New stomach cancer combo shows promise in early trial

NCT ID NCT00512304

Completed Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 study tested a combination of chemotherapy (FOLFIRI) and radiation with 5-fluorouracil in 63 patients with gastric cancer. The treatment was given either before or after surgery to remove the tumor. The goal was to see if this approach is feasible and less toxic than older regimens. The study focused on patients with locally advanced disease (T3 or N+) who had not yet developed metastases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FOLFIRI chemotherapy plus 5-fluorouracil and radiation
What this could lead to: If successful, this could point toward a more effective and less toxic treatment plan for gastric cancer patients after surgery.
What could go wrong: This is a small, early-phase feasibility study, so results may not apply to all patients. The treatment still involves significant side effects from chemotherapy and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER

Contacts and locations

Locations

University hospital

Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.